Arrowhead Pharmaceuticals Inc
ARWR
Company Profile
Business description
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Contact
177 E Colorado Boulevard
Suite 700
PasadenaCA91105
USAT: +1 626 304-3400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
711
Stocks News & Analysis
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,849.30 | 74.60 | -0.84% |
| CAC 40 | 8,044.70 | 73.08 | -0.90% |
| DAX 40 | 25,217.00 | 223.81 | -0.88% |
| Dow JONES (US) | 52,421.20 | 152.09 | -0.29% |
| FTSE 100 | 10,603.63 | 93.94 | -0.88% |
| HKSE | 24,667.24 | 250.36 | -1.00% |
| NASDAQ | 26,186.41 | 146.62 | -0.56% |
| Nikkei 225 | 63,484.10 | 8.89 | -0.01% |
| NZX 50 Index | 13,484.22 | 76.47 | -0.56% |
| S&P 500 | 7,619.98 | 37.00 | -0.48% |
| S&P/ASX 200 | 8,672.50 | 77.40 | -0.88% |
| SSE Composite Index | 3,864.28 | 21.05 | -0.54% |